Sab Bio Is A Clinical Stage Biopharmaceutical Company Focused On Developing Innovative Treatments For Immune And Autoimmune Disordersfounded In 2014 And Traded On Nasdaq Under The Symbol Sabsthe Company Rebranded From Sab Biotherapeutics In June 2024 To Better Reflect Its Strategic Directionparticularly In Addressing Serious Unmet Needs In Type 1 Diabetest1Dthe Company Specializes In Creating Humanmulti Targeted Immunoglobulinsiggsthrough Advanced Genetic Engineeringits Lead Assetsab 142Is A Disease Modifying Immunotherapy Aimed At Delaying The Onset And Progression Of T1Dthis Therapy Targets The Underlying Immune Response That Damages Insulin Producing Beta Cellswith The Goal Of Preserving Their Function Over Timesab Bio Is Committed To Advancing Its Research And Development Efforts To Improve Treatment Options For Patients With Autoimmune Disorders
No conferences found for this company.
| Company Name | Sab Biotherapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
